Saturday, February 26, 2011

Opana


See also: Generic Opana ER


Opana is a brand name of oxymorphone, approved by the FDA in the following formulation(s):


OPANA (oxymorphone hydrochloride - injectable; injection)



  • Manufacturer: ENDO PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 1MG/ML [RLD]

OPANA (oxymorphone hydrochloride - tablet; oral)



  • Manufacturer: ENDO PHARMS

    Approval date: June 22, 2006

    Strength(s): 10MG [RLD][AB], 5MG [AB]

Has a generic version of Opana been approved?


Yes. The following products are equivalent to Opana:


oxymorphone hydrochloride tablet; oral



  • Manufacturer: ROXANE

    Approval date: September 27, 2010

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: TEVA

    Approval date: February 15, 2011

    Strength(s): 10MG [AB], 5MG [AB]

Note: No generic formulation of the following product is available.


  • oxymorphone hydrochloride - injectable; injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Opana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Opana.

See also...

  • Opana Consumer Information (Drugs.com)
  • Opana Consumer Information (Wolters Kluwer)
  • Opana Consumer Information (Cerner Multum)
  • Opana Advanced Consumer Information (Micromedex)
  • Opana AHFS DI Monographs (ASHP)
  • Oxymorphone Consumer Information (Wolters Kluwer)
  • Oxymorphone Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Oxymorphone Suppositories Consumer Information (Wolters Kluwer)
  • Oxymorphone Tablets Consumer Information (Wolters Kluwer)
  • Oxymorphone Consumer Information (Cerner Multum)
  • Oxymorphone Advanced Consumer Information (Micromedex)
  • Oxymorphone Injection Advanced Consumer Information (Micromedex)
  • Oxymorphone Hydrochloride AHFS DI Monographs (ASHP)

Friday, February 25, 2011

Daktozin




In the US, Daktozin is a member of the drug class topical antifungals and is used to treat Diaper Rash.

Ingredient matches for Daktozin



Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Daktozin in the following countries:


  • Belgium

  • Colombia

  • Luxembourg

  • New Zealand

  • Peru

Zinc Oxide

Zinc Oxide is reported as an ingredient of Daktozin in the following countries:


  • Luxembourg

  • New Zealand

International Drug Name Search

Aplenzin


Aplenzin is a brand name of bupropion, approved by the FDA in the following formulation(s):


APLENZIN (bupropion hydrobromide - tablet, extended release; oral)



  • Manufacturer: VALEANT INTL

    Approval date: April 23, 2008

    Strength(s): 174MG, 348MG [RLD], 522MG

Has a generic version of Aplenzin been approved?


No. There is currently no therapeutically equivalent version of Aplenzin available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aplenzin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Modified release formulations of a bupropion salt
    Patent 7,241,805
    Issued: July 10, 2007
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Turchetta; Stefano & Jackson; Graham & Massardo; Pietro & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories, Inc.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,569,610
    Issued: August 4, 2009
    Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International SRL
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS




  • Modified release formulations of a bupropion salt
    Patent 7,572,935
    Issued: August 11, 2009
    Inventor(s): Oberegger; Werner & Maes; Paul & Turchetta; Stefano & Massardo; Pietro & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,585,897
    Issued: September 8, 2009
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.r.l.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Bupropion hydrobromide and therapeutic applications
    Patent 7,645,802
    Issued: January 12, 2010
    Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty & Jackson; Graham
    Assignee(s): Biovail Laboratories International SRL.
    Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,649,019
    Issued: January 19, 2010
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,662,407
    Issued: February 16, 2010
    Inventor(s): Oberegger; Werner & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Bupropion hydrobromide and therapeutic applications
    Patent 7,671,094
    Issued: March 2, 2010
    Inventor(s): Williams; Robert Parry & Silverstone; Peter Harris
    Assignee(s): Biovail Laboratories International S.R.L.
    Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product



See also...

  • Aplenzin Consumer Information (Drugs.com)
  • Aplenzin Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Aplenzin Consumer Information (Cerner Multum)
  • Aplenzin Advanced Consumer Information (Micromedex)
  • Bupropion Consumer Information (Drugs.com)
  • Bupropion Consumer Information (Wolters Kluwer)
  • Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Consumer Information (Cerner Multum)
  • Bupropion Advanced Consumer Information (Micromedex)
  • Bupropion Hydrochloride AHFS DI Monographs (ASHP)

Thursday, February 24, 2011

Calcium Chloride




In some countries, this medicine may only be approved for veterinary use.


In the US, Calcium Chloride (calcium chloride systemic) is a member of the drug class minerals and electrolytes and is used to treat Asystole, Electromechanical Dissociation, Hyperkalemia, Hypermagnesemia and Hypocalcemia.

US matches:

  • Calcium Chloride

ATC (Anatomical Therapeutic Chemical Classification)

A12AA07,B05XA07,G04BA03

CAS registry number (Chemical Abstracts Service)

0010043-52-4

Chemical Formula

Ca-Cl2

Molecular Weight

110

Therapeutic Categories

Electrolyte solution

Mineral supplement

Urological, acidifier

Treatment of parturient paresis (milk fever) in animals

Chemical Name

Calcium chloride

Foreign Names

  • Calcii chloridum (Latin)
  • Calciumchlorid (German)
  • Chlorure de calcium (French)
  • Calcio cloruro (Spanish)

Generic Names

  • Calcium chloratum (IS)
  • Calcium dichloride (IS)
  • Chlorid vapenaty (IS)
  • E 509 (IS)
  • EINECS 233-140-8 (IS)
  • Calcium Chloride (PH: USP 32)
  • UNII-M4I0D6VV5M (IS)
  • Calcii chloridum dihydricum (PH: Ph. Eur. 6)
  • Calcium Chloride (PH: USP 31)
  • Calcium Chloride Dihydrate (PH: BP 2010, Ph. Eur. 6)
  • Calcium Chloride Hydrate (PH: JP XV)
  • Calciumchlorid-Dihydrat (PH: Ph. Eur. 6)
  • Calcium dichloride hexahydrate (IS)
  • Calcii chloridum hexahydricum (PH: Ph. Eur. 6)
  • Calcium chloride hexahydrate (PH: BP 2007, BP 2007, Ph. Eur. 6)
  • Calcium Chloride Hexahydrate (PH: BP 2010)
  • Calciumchlorid-Hexahydrat (PH: Ph. Eur. 6)

Brand Names

  • Calcio + Magnesio Cloruro Fresenius (Calcium Chloride and Magnesium Chloride)
    Fresenius, Italy


  • Calcio + Magnesio Cloruro Galenica (Calcium Chloride and Magnesium Chloride)
    Galenica Senese, Italy


  • Calcio + Magnesio Cloruro Monico (Calcium Chloride and Magnesium Chloride)
    Monico, Italy


  • Calcio + Magnesio Cloruro Salf (Calcium Chloride and Magnesium Chloride)
    Salf, Italy


  • Calcium Chloratum
    Polfa Lódz, Poland


  • Calcium Chloride
    CSL, Australia; Hospira, Canada; IMS, Oman; Phebra, Australia


  • Calcium enriched Molasses (veterinary use)
    Agri-Feeds Limited, New Zealand


  • Calcium Gel (veterinary use)
    Intervet, France


  • Calciumchlorid Fresenius
    Fresenius Kabi, Austria


  • Calcoral (veterinary use)
    Ausrichter, New Zealand


  • Calol (Calcium Chloride and Magnesium (veterinary use))
    Prodivet - Coméercio de Produtos Químicos, Farmacêuticos e Cosméticos, Lda., Portugal; Provet, Switzerland


  • Chlorure de Calcium
    Unimed, Tunisia


  • Conclyte-Ca
    Nipro PharmaNipurofama, Japan


  • Oral Cal (veterinary use)
    Bomac, New Zealand


  • Toniflash (Calcium Chloride and Magnesium Chloride (veterinary use))
    Fort Dodge Santé Animale, France


  • Accusol 35
    Baxter, Norway


  • Accusol 35 Kalium
    Baxter, Norway


  • Calcio Cloruro Bioindustria Lim
    Bioindustria Lim, Italy


  • Calcio Cloruro Galenica
    Galenica Senese, Italy


  • Calcio Cloruro Monico
    Monico, Italy


  • Calcio Cloruro Salf
    Salf, Italy


  • Calcium Chloratum
    Ivax, Slovakia


  • Calcium Chloride
    AFT, New Zealand; Otsuka, Japan


  • Calciumchlorid Baxter
    Baxter, Germany


  • Calciumchlorid SAD
    SAD, Denmark


  • Calmasel (Calcium Chloride and Magnesium Chloride hexahydrate (veterinary use))
    Selecta, Germany


  • Intergravin (veterinary use)
    Alvetra u. Werfft, Austria


  • Kovel (Calcium Chloride and Magnesium chloride (veterinary use))
    Gräub, Switzerland


  • Sabax Calcium Chlorid
    Adcock Ingram Critical Care, South Africa


  • Calcimag (Calcium Chloride and Magnesium Chlorid (veterinary use))
    Kela, Norway


  • Calcium Chloratum Biotika
    Biotika, Slovakia


  • Calcium Chlorure Cooper
    Cooper, France


  • Calcium Richter forte (veterinary use)
    Richter, Austria


  • Calcoral (veterinary use)
    Ausrichter, Australia


  • CAL-MAG (Calcium Chloride and Magnesium (veterinary use))
    Streuli Vet, Switzerland


  • Chlor-Mag-Kalz-Lösung (Calcium Chloride and Magnesium Chloride hexahydrate (veterinary use))
    WDT, Germany


  • Chlorure de Calcium Renaudin
    Renaudin, France


  • Cloruro Calcico Braun
    Braun, Spain


  • Oral Cal (veterinary use)
    Bomac Animal Health, Australia


  • Vélical (Calcium Chloride and Magnesium Chloride (veterinary use))
    Fort Dodge Santé Animale, France

International Drug Name Search

Glossary

ISInofficial Synonym
PHPharmacopoeia Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Sunday, February 20, 2011

Acide méclofénamique




Acide méclofénamique may be available in the countries listed below.


Ingredient matches for Acide méclofénamique



Meclofenamic Acid

Acide méclofénamique (DCF) is also known as Meclofenamic Acid (Rec.INN)

International Drug Name Search

Glossary

DCFDénomination Commune Française
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Wednesday, February 16, 2011

Paracetamol-Darnitsa




Paracetamol-Darnitsa may be available in the countries listed below.


Ingredient matches for Paracetamol-Darnitsa



Paracetamol

Paracetamol is reported as an ingredient of Paracetamol-Darnitsa in the following countries:


  • Georgia

International Drug Name Search

Monday, February 14, 2011

Profasi




In the US, Profasi (chorionic gonadotropin (hcg) systemic) is a member of the drug class gonadotropins and is used to treat Female Infertility, Hypogonadism - Male, Ovulation Induction and Prepubertal Cryptorchidism.

US matches:

  • Profasi HP

  • Profasi

Ingredient matches for Profasi



Chorionic Gonadotrophin

Chorionic Gonadotrophin is reported as an ingredient of Profasi in the following countries:


  • Greece

  • India

  • Ireland

  • Luxembourg

  • Peru

International Drug Name Search

Saturday, February 12, 2011

K-Profen




K-Profen may be available in the countries listed below.


Ingredient matches for K-Profen



Ketoprofen

Ketoprofen is reported as an ingredient of K-Profen in the following countries:


  • Costa Rica

  • Dominican Republic

  • El Salvador

  • Guatemala

  • Honduras

  • Mexico

  • Panama

International Drug Name Search

Thursday, February 10, 2011

Torasémide




Torasémide may be available in the countries listed below.


Ingredient matches for Torasémide



Torasemide

Torasémide (DCF) is also known as Torasemide (Rec.INN)

International Drug Name Search

Glossary

DCFDénomination Commune Française
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Monday, February 7, 2011

Equitak




Equitak may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Equitak



Abamectin

Abamectin is reported as an ingredient of Equitak in the following countries:


  • New Zealand

Oxfendazole

Oxfendazole is reported as an ingredient of Equitak in the following countries:


  • New Zealand

Praziquantel

Praziquantel is reported as an ingredient of Equitak in the following countries:


  • New Zealand

International Drug Name Search

Sunday, February 6, 2011

Intal


Intal is a brand name of cromolyn, approved by the FDA in the following formulation(s):


INTAL (cromolyn sodium - aerosol, metered; inhalation)



  • Manufacturer: KING PHARMS

    Approval date: December 5, 1985

    Strength(s): 0.8MG/INH [RLD]

Has a generic version of Intal been approved?


No. There is currently no therapeutically equivalent version of Intal available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Intal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Intal.

See also...

  • Intal Aerosol Solution Consumer Information (Wolters Kluwer)
  • Intal Nebulizer Solution Consumer Information (Wolters Kluwer)
  • Intal inhalation Consumer Information (Cerner Multum)
  • Intal Advanced Consumer Information (Micromedex)
  • Cromolyn Aerosol Solution Consumer Information (Wolters Kluwer)
  • Cromolyn Concentrate Consumer Information (Wolters Kluwer)
  • Cromolyn Nebulizer Solution Consumer Information (Wolters Kluwer)
  • Cromolyn sodium Consumer Information (Cerner Multum)
  • Cromolyn sodium inhalation Consumer Information (Cerner Multum)
  • Cromolyn sodium oral Consumer Information (Cerner Multum)
  • Cromolyn Advanced Consumer Information (Micromedex)
  • Cromolyn Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
  • Cromolyn Sodium AHFS DI Monographs (ASHP)

Aerovent




Aerovent may be available in the countries listed below.


Ingredient matches for Aerovent



Budesonide

Budesonide is reported as an ingredient of Aerovent in the following countries:


  • Argentina

Ipratropium

Ipratropium Bromide is reported as an ingredient of Aerovent in the following countries:


  • Israel

Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Aerovent in the following countries:


  • Philippines

International Drug Name Search

Timoptic


See also: Generic Timoptic-XE


Timoptic is a brand name of timolol ophthalmic, approved by the FDA in the following formulation(s):


TIMOPTIC (timolol maleate - solution/drops; ophthalmic)



  • Manufacturer: ATON

    Approved Prior to Jan 1, 1982

    Strength(s): EQ 0.25% BASE [RLD][AT], EQ 0.5% BASE [RLD][AT]

Has a generic version of Timoptic been approved?


Yes. The following products are equivalent to Timoptic:


timolol maleate solution/drops; ophthalmic



  • Manufacturer: AKORN

    Approval date: March 25, 1997

    Strength(s): EQ 0.25% BASE [AT], EQ 0.5% BASE [AT], EQ 0.5% BASE [AT]


  • Manufacturer: APOTEX INC

    Approval date: September 8, 2000

    Strength(s): EQ 0.25% BASE [AT], EQ 0.5% BASE [AT]


  • Manufacturer: BAUSCH AND LOMB

    Approval date: March 25, 1997

    Strength(s): EQ 0.25% BASE [AT], EQ 0.5% BASE [AT]


  • Manufacturer: FALCON PHARMS

    Approval date: April 28, 1995

    Strength(s): EQ 0.25% BASE [AT], EQ 0.5% BASE [AT]


  • Manufacturer: FDC LTD

    Approval date: April 30, 2008

    Strength(s): EQ 0.25% BASE [AT], EQ 0.5% BASE [AT]


  • Manufacturer: HI TECH PHARMA

    Approval date: September 10, 2002

    Strength(s): EQ 0.5% BASE [AT]


  • Manufacturer: PACIFIC PHARMA

    Approval date: March 25, 1997

    Strength(s): EQ 0.25% BASE [AT], EQ 0.5% BASE [AT]


  • Manufacturer: WOCKHARDT

    Approval date: September 28, 2009

    Strength(s): EQ 0.25% BASE [AT], EQ 0.5% BASE [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Timoptic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Timoptic.

See also...

  • Timoptic Drops Consumer Information (Wolters Kluwer)
  • Timoptic Ocumeter Consumer Information (Cerner Multum)
  • Timoptic Ocumeter Plus Consumer Information (Cerner Multum)
  • Timoptic Ocumeter Advanced Consumer Information (Micromedex)
  • Timoptic Ocumeter Plus Advanced Consumer Information (Micromedex)
  • Timolol Drops Consumer Information (Wolters Kluwer)
  • Timolol Gel Eye Drops Consumer Information (Wolters Kluwer)
  • Timolol ophthalmic Consumer Information (Cerner Multum)
  • Timolol Ophthalmic Advanced Consumer Information (Micromedex)
  • Timolol eent AHFS DI Monographs (ASHP)

Saturday, February 5, 2011

Verdeso


Verdeso is a brand name of desonide topical, approved by the FDA in the following formulation(s):


VERDESO (desonide - aerosol, foam; topical)



  • Manufacturer: STIEFEL LABS INC

    Approval date: September 19, 2006

    Strength(s): 0.05% [RLD]

Has a generic version of Verdeso been approved?


No. There is currently no therapeutically equivalent version of Verdeso available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Verdeso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Mousse composition
    Patent 6,730,288
    Issued: May 4, 2004
    Inventor(s): Albert Zorko; Abram
    Assignee(s): Connetics Australia Pty Ltd
    A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient; an occlusive agent; an aqueous solvent; and an organic cosolvent, the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.
    Patent expiration dates:

    • September 8, 2019
      ✓ 
      Drug product




  • Mousse composition
    Patent 7,029,659
    Issued: April 18, 2006
    Inventor(s): Abram; Albert Zorko
    Assignee(s): Connetics Australia Pty Ltd.
    A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.
    Patent expiration dates:

    • September 8, 2019
      ✓ 
      Drug product



See also...

  • Verdeso Consumer Information (Drugs.com)
  • Verdeso Foam Consumer Information (Wolters Kluwer)
  • Verdeso Consumer Information (Cerner Multum)
  • Verdeso Advanced Consumer Information (Micromedex)
  • Desonide Cream Consumer Information (Wolters Kluwer)
  • Desonide Foam Consumer Information (Wolters Kluwer)
  • Desonide Gel Consumer Information (Wolters Kluwer)
  • Desonide Lotion Consumer Information (Wolters Kluwer)
  • Desonide topical Consumer Information (Cerner Multum)
  • Pms-Desonide Advanced Consumer Information (Micromedex)
  • Desonide Topical application Advanced Consumer Information (Micromedex)
  • Desonide AHFS DI Monographs (ASHP)

Friday, February 4, 2011

Seresnatt




Seresnatt may be available in the countries listed below.


Ingredient matches for Seresnatt



Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Seresnatt in the following countries:


  • Japan

International Drug Name Search

Rebetol


Generic Name: ribavirin (oral) (rye ba VYE rin)

Brand Names: Copegus, Rebetol, RibaPak, Ribasphere, RibaTab


What is ribavirin?

Ribavirin is an antiviral medication.


Ribavirin must be used together with an interferon alfa product (such as Pegasys, PegIntron, Sylatron, or Intron A) to treat chronic hepatitis C.


Ribavirin may also be used for purposes not listed in this medication guide.


What is the most important information I should know about ribavirin?


Ribavirin is not effective when used alone to treat hepatitis C. It must be used together with an interferon alfa product (such as Pegasys, PegIntron, Sylatron, or Intron A) to treat chronic hepatitis C. You should not take ribavirin if you are allergic to it, or if you have severe liver disease, autoimmune hepatitis, a hemoglobin disorder (anemia, thalassemia, and others), if you are also taking didanosine (Videx), or if you are pregnant woman, or a man whose female sexual partner is pregnant. This medication can cause birth defects or death in an unborn baby. If you are a woman, do not take ribavirin if you are pregnant. If you are a man, do not take ribavirin if your female sexual partner is pregnant. An unborn baby could also be harmed if a man fathers the child while he is taking ribavirin.

Use at least two effective forms of birth control while either sexual partner is taking ribavirin, and for at least 6 months after treatment ends. Tell your doctor right away if a pregnancy occurs while either the mother or the father is taking ribavirin.


Ribavirin may decrease the number of red blood cells in your body. This is called anemia and it can be life-threatening in people who have heart disease or circulation problems. Your blood will need to be tested often. Your vision, liver function, and thyroid function may also need to be tested. Visit your doctor regularly. Call your doctor at once if you have pale or yellowed skin, dark colored urine, fever, confusion, chest pain, weakness, or trouble breathing.

What should I discuss with my healthcare provider before taking ribavirin?


You should not take ribavirin if you are allergic to it, or if you have:

  • severe liver disease (especially cirrhosis);




  • autoimmune hepatitis;




  • a hemoglobin disorder such as anemia, thalassemia (Mediterranean anemia), or sickle-cell anemia;




  • if you are also taking didanosine (Videx); or




  • if you are pregnant woman, or a man whose female sexual partner is pregnant.



To make sure you can safely take ribavirin, tell your doctor if you have any of these other conditions:


  • kidney or liver disease (other than hepatitis C);


  • hepatitis B infection;




  • a blood cell disorder such as hemolytic anemia (a lack of red blood cells);




  • human immunodeficiency virus (HIV or AIDS);




  • diabetes;




  • a pancreas disorder;




  • sarcoidosis;




  • breathing problems;




  • a thyroid disorder;




  • new or worsening eye problems (such as retinopathy);




  • a history of heart disease, high blood pressure, or a heart attack;




  • a history of depression or suicide attempt;




  • a history of a liver, kidney, or other organ transplant; or




  • if you have ever received treatment for hepatitis C that did not work well.




This medication can cause birth defects or death in an unborn baby.

  • If you are a woman, do not take ribavirin if you are pregnant. You will need frequent pregnancy tests to make sure you are not pregnant while taking ribavirin.




  • If you are a man, do not take ribavirin if your female sexual partner is pregnant. An unborn baby could also be harmed if a man fathers the child while he is taking ribavirin. Your sexual partner will need frequent pregnancy tests to make sure she is not pregnant while you are taking ribavirin.




  • Use at least two effective forms of birth control while either sexual partner is taking ribavirin, and for at least 6 months after treatment ends.




  • Tell your doctor right away if a pregnancy occurs while either the mother or the father is taking ribavirin.



Your name may need to be listed on a ribavirin pregnancy registry if you become pregnant while you or your male sexual partner are taking this medication or during the 6 months after treatment ends. This is to track the outcome of the pregnancy and to evaluate any effects of ribavirin on the baby.


It is not known whether ribavirin passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are taking ribavirin. Ribavirin may affect growth in children.

How should I take ribavirin?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Ribavirin is not effective when used alone to treat hepatitis C. It must be used together with an interferon alfa product (such as Peg-Intron or Intron A) to treat chronic hepatitis C. Take this medicine with food.

Measure the liquid form of ribavirin with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Ribavirin may decrease the number of red blood cells in your body. This is called anemia and it can be life-threatening in people who have heart disease or circulation problems. Your blood will need to be tested often. Your vision, liver function, and thyroid function may also need to be tested. Visit your doctor regularly. Call your doctor at once if you have pale or yellowed skin, dark colored urine, fever, confusion, chest pain, shortness of breath, or weakness. These may be signs of serious anemia.

Use ribavirin regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.


Drink extra fluids while you are taking ribavirin to keep from getting dehydrated, especially during exercise or in hot weather.


Ribavirin can cause dry mouth, which could lead to tooth decay or gum disease. If you vomit while taking ribavirin, rinse your mouth out with water to prevent damage to your teeth or gums. Be sure to have regular dental exams while you are taking this medication.


Store ribavirin tablets and capsules at room temperature away from moisture, heat, and light. Store ribavirin liquid (oral solution) in the refrigerator. Do not allow it to freeze.

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. If you have not taken the medication for longer than 24 hours, call your doctor for instructions. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. Overdose symptoms may include easy bruising or bleeding, urinating less than usual or not at all, chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, or a general ill feeling.

What should I avoid while taking ribavirin?


Treatment with ribavirin does not prevent spread of the hepatitis C virus to other people. Follow your doctor's instructions about how to prevent passing the disease to another person.


Avoid drinking alcohol. It may increase your risk of liver damage. Ribavirin may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Ribavirin side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using ribavirin and call your doctor at once if you have a serious side effect such as:

  • problems with your vision;




  • fever, chills, body aches, flu symptoms;




  • severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;




  • stabbing chest pain, wheezing, feeling short of breath;




  • severe depression, hallucinations, thoughts of suicide or hurting yourself;




  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling; or




  • pale or yellowed skin, dark colored urine, easy bruising or bleeding, confusion, or unusual weakness.



Less serious side effects may include:



  • headache;




  • muscle pain;




  • dry mouth;




  • nausea; vomiting, stomach pain, loss of appetite;




  • weight loss;




  • feeling tired or irritable;




  • anxiety, mood changes; or




  • pain, swelling, or irritation where the interferon injection was given.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect ribavirin?


Tell your doctor about all other medicines you use, especially:



  • abacavir (Ziagen);




  • azathiopriine (Azasan, Imuran);




  • lamivudine (Combivir, Epivir, Epzicom, Trizivir);




  • stavudine (Zerit);




  • tenofovir (Viread);




  • zalcitabine (Hivid); or




  • zidovudine (Retrovir, AZT).



This list is not complete and other drugs may interact with ribavirin. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Rebetol resources


  • Rebetol Side Effects (in more detail)
  • Rebetol Use in Pregnancy & Breastfeeding
  • Drug Images
  • Rebetol Drug Interactions
  • Rebetol Support Group
  • 0 Reviews for Rebetol - Add your own review/rating


  • Rebetol Consumer Overview

  • Rebetol Prescribing Information (FDA)

  • Rebetol MedFacts Consumer Leaflet (Wolters Kluwer)

  • Rebetol Advanced Consumer (Micromedex) - Includes Dosage Information

  • Ribavirin Professional Patient Advice (Wolters Kluwer)

  • Ribavirin Monograph (AHFS DI)

  • Ribavirin Prescribing Information (FDA)

  • Copegus MedFacts Consumer Leaflet (Wolters Kluwer)

  • Copegus Prescribing Information (FDA)

  • Ribasphere Prescribing Information (FDA)

  • Ribasphere Consumer Overview

  • Virazole Prescribing Information (FDA)

  • Virazole Advanced Consumer (Micromedex) - Includes Dosage Information

  • Virazole Solution MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Rebetol with other medications


  • Hepatitis C


Where can I get more information?


  • Your pharmacist can provide more information about ribavirin.

See also: Rebetol side effects (in more detail)


Thursday, February 3, 2011

Allergosan




Allergosan may be available in the countries listed below.


Ingredient matches for Allergosan



Chloropyramine

Chloropyramine is reported as an ingredient of Allergosan in the following countries:


  • Georgia

Chloropyramine hydrochloride (a derivative of Chloropyramine) is reported as an ingredient of Allergosan in the following countries:


  • Bulgaria

  • Latvia

International Drug Name Search

Wednesday, February 2, 2011

Doxonolver




Doxonolver may be available in the countries listed below.


Ingredient matches for Doxonolver



Doxorubicin

Doxorubicin is reported as an ingredient of Doxonolver in the following countries:


  • Venezuela

International Drug Name Search

Tuesday, February 1, 2011

Colaxin




Colaxin may be available in the countries listed below.


Ingredient matches for Colaxin



Cefalexin

Cefalexin is reported as an ingredient of Colaxin in the following countries:


  • Myanmar

International Drug Name Search